Brenda Cooperstone

CIK: 0001931514

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

LXEO

Lexeo Therapeutics, Inc.

Director

SNTI

Senti Biosciences, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

LXEO
Lexeo Therapeutics, Inc.
Jun 25, 2026
Award(A)
Stock Option (right to buy)
Direct
35K shares-
LXEO
Lexeo Therapeutics, Inc.
Jun 26, 2025
Award(A)
Stock Option (right to buy)
Direct
25K shares-
SNTI
Senti Biosciences, Inc.
Jun 25, 2025
Award(A)
Stock Option (Right to Buy)
Direct
22K shares-
SNTI
Senti Biosciences, Inc.
Mar 7, 2025
Award(A)
Stock Option (Right to Buy)
Direct
43.9K shares-

		Type	Shares	Price		Ownership
Jun 25, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A) Stock Option (right to buy)	35,000	-	-	Direct
Jun 26, 2025	LXEO Lexeo Therapeutics, Inc.	Award(A) Stock Option (right to buy)	25,000	-	-	Direct
Jun 25, 2025	SNTI Senti Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	21,950	-	-	Direct
Mar 7, 2025	SNTI Senti Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	43,900	-	-	Direct

1-4 of 4 transactions

About COOPERSTONE BRENDA

COOPERSTONE BRENDA (SEC CIK 0001931514) files insider reports with the SEC as Director of Lexeo Therapeutics, Inc. (LXEO) and Director of Senti Biosciences, Inc. (SNTI).

Signal8 holds 4 ownership filings by COOPERSTONE BRENDA, all Form 4s, filed between Mar 11, 2025 and Jun 29, 2026. Those filings report 4 transactions, from Mar 7, 2025 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on COOPERSTONE BRENDA's filings is in NEW YORK, NY.

Recent filings by COOPERSTONE BRENDA

Jun 25, 2026: Grant or award of LXEO derivative securities (Form 4, code A).
Jun 26, 2025: Grant or award of LXEO derivative securities (Form 4, code A).
Jun 25, 2025: Grant or award of SNTI derivative securities (Form 4, code A).
Mar 7, 2025: Grant or award of SNTI derivative securities (Form 4, code A).

Other insiders filing for Lexeo Therapeutics, Inc. (LXEO)

Tamayo Louis Edward, Chief Financial Officer
Bhalla Narinder Pal, Chief Medical Officer
Otero Jose Manuel, Chief Operating Officer
Townsend Richard Nolan, Chief Executive Officer
Altschuler Steven, Director
Agger Mette Kirstine, Director

How to read Form 4 transaction codes